FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293720562> ?p ?o ?g. }

• W4293720562 endingPage "186" @default.
• W4293720562 startingPage "179" @default.
• W4293720562 abstract "To assess the risk of vaccine-associated uveitis (VAU) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and evaluate uveitis onset interval and clinical presentations in the patients.A retrospective study from December 11, 2020, to May 9, 2022, using the Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System.Patients diagnosed with VAU after administration of BNT162b2 (Pfizer-BioNTech, Pfizer Inc/BioNTech SE), mRNA-1273 (Moderna, Moderna Therapeutics Inc), and Ad26.COV2.S (Janssen, Janssen Pharmaceuticals) vaccine worldwide.A descriptive analysis of the demographics, clinical history, and presentation was performed. We evaluated the correlation among the 3 vaccines and continuous and categorical variables. A post hoc analysis was performed between uveitis onset interval after vaccination and age, dose, and vaccine type. Finally, a 30-day risk analysis for VAU onset postvaccination was performed.The estimated global crude reporting rate, observed to expected ratio of VAU in the United States, associated ocular and systemic presentations, and onset duration.A total of 1094 cases of VAU were reported from 40 countries with an estimated crude reporting rate (per million doses) of 0.57, 0.44, and 0.35 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The observed to expected ratio of VAU was comparable for BNT162b2 (0.023), mRNA-1273 (0.025), and Ad26.COV2.S (0.027). Most cases of VAU were reported in patients who received BNT162b2 (n = 853, 77.97%). The mean age of patients with VAU was 46.24 ± 16.93 years, and 68.65% (n = 751) were women. Most cases were reported after the first dose (n = 452, 41.32%) and within the first week (n = 591, 54.02%) of the vaccination. The onset interval for VAU was significantly longer in patients who received mRNA-1273 (21.22 ± 42.74 days) compared with BNT162b2 (11.42 ± 23.16 days) and rAd26.COV2.S (12.69 ± 16.02 days) vaccines (P < 0.0001). The post hoc analysis revealed a significantly shorter interval of onset for the BNT162b2 compared with the mRNA 1273 vaccine (P < 0.0001). The 30-day risk analysis showed a significant difference among the 3 vaccines (P < 0.0001).The low crude reporting rate and observed to expected ratio suggest a low safety concern for VAU. This study provides insights into a possible temporal association between reported VAU events and SARS-CoV-2 vaccines; however, further investigations are required to delineate the associated immunological mechanisms." @default.
• W4293720562 created "2022-08-31" @default.
• W4293720562 creator A5012701637 @default.
• W4293720562 creator A5020292429 @default.
• W4293720562 creator A5023638754 @default.
• W4293720562 creator A5037563352 @default.
• W4293720562 creator A5048241377 @default.
• W4293720562 date "2023-02-01" @default.
• W4293720562 modified "2023-10-06" @default.
• W4293720562 title "Vaccine-Associated Uveitis after COVID-19 Vaccination" @default.
• W4293720562 cites W1571622639 @default.
• W4293720562 cites W19537414 @default.
• W4293720562 cites W1970324099 @default.
• W4293720562 cites W2035711342 @default.
• W4293720562 cites W2051918598 @default.
• W4293720562 cites W2066366729 @default.
• W4293720562 cites W2066560916 @default.
• W4293720562 cites W2121492881 @default.
• W4293720562 cites W2167499598 @default.
• W4293720562 cites W2437444230 @default.
• W4293720562 cites W2490505209 @default.
• W4293720562 cites W2590594220 @default.
• W4293720562 cites W2950557378 @default.
• W4293720562 cites W2955068995 @default.
• W4293720562 cites W3033003390 @default.
• W4293720562 cites W3092223014 @default.
• W4293720562 cites W3105041435 @default.
• W4293720562 cites W3111255098 @default.
• W4293720562 cites W3126729284 @default.
• W4293720562 cites W3134440370 @default.
• W4293720562 cites W3140429722 @default.
• W4293720562 cites W3153508314 @default.
• W4293720562 cites W3157544759 @default.
• W4293720562 cites W3159694506 @default.
• W4293720562 cites W3160916219 @default.
• W4293720562 cites W3160918102 @default.
• W4293720562 cites W3161877876 @default.
• W4293720562 cites W3178318996 @default.
• W4293720562 cites W3192369908 @default.
• W4293720562 cites W3199051828 @default.
• W4293720562 cites W3200090586 @default.
• W4293720562 cites W3204579856 @default.
• W4293720562 cites W4200406851 @default.
• W4293720562 cites W4207051048 @default.
• W4293720562 cites W4213274805 @default.
• W4293720562 cites W4214607432 @default.
• W4293720562 cites W4214806105 @default.
• W4293720562 cites W4281552051 @default.
• W4293720562 doi "https://doi.org/10.1016/j.ophtha.2022.08.027" @default.
• W4293720562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36055601" @default.
• W4293720562 hasPublicationYear "2023" @default.
• W4293720562 type Work @default.
• W4293720562 citedByCount "16" @default.
• W4293720562 countsByYear W42937205622022 @default.
• W4293720562 countsByYear W42937205622023 @default.
• W4293720562 crossrefType "journal-article" @default.
• W4293720562 hasAuthorship W4293720562A5012701637 @default.
• W4293720562 hasAuthorship W4293720562A5020292429 @default.
• W4293720562 hasAuthorship W4293720562A5023638754 @default.
• W4293720562 hasAuthorship W4293720562A5037563352 @default.
• W4293720562 hasAuthorship W4293720562A5048241377 @default.
• W4293720562 hasBestOaLocation W42937205621 @default.
• W4293720562 hasConcept C126322002 @default.
• W4293720562 hasConcept C156957248 @default.
• W4293720562 hasConcept C167135981 @default.
• W4293720562 hasConcept C187212893 @default.
• W4293720562 hasConcept C197934379 @default.
• W4293720562 hasConcept C203014093 @default.
• W4293720562 hasConcept C22070199 @default.
• W4293720562 hasConcept C2776194053 @default.
• W4293720562 hasConcept C44249647 @default.
• W4293720562 hasConcept C71924100 @default.
• W4293720562 hasConceptScore W4293720562C126322002 @default.
• W4293720562 hasConceptScore W4293720562C156957248 @default.
• W4293720562 hasConceptScore W4293720562C167135981 @default.
• W4293720562 hasConceptScore W4293720562C187212893 @default.
• W4293720562 hasConceptScore W4293720562C197934379 @default.
• W4293720562 hasConceptScore W4293720562C203014093 @default.
• W4293720562 hasConceptScore W4293720562C22070199 @default.
• W4293720562 hasConceptScore W4293720562C2776194053 @default.
• W4293720562 hasConceptScore W4293720562C44249647 @default.
• W4293720562 hasConceptScore W4293720562C71924100 @default.
• W4293720562 hasIssue "2" @default.
• W4293720562 hasLocation W42937205621 @default.
• W4293720562 hasLocation W42937205622 @default.
• W4293720562 hasLocation W42937205623 @default.
• W4293720562 hasOpenAccess W4293720562 @default.
• W4293720562 hasPrimaryLocation W42937205621 @default.
• W4293720562 hasRelatedWork W1584443261 @default.
• W4293720562 hasRelatedWork W1982619745 @default.
• W4293720562 hasRelatedWork W2002325000 @default.
• W4293720562 hasRelatedWork W2076929529 @default.
• W4293720562 hasRelatedWork W2114056959 @default.
• W4293720562 hasRelatedWork W2516340432 @default.
• W4293720562 hasRelatedWork W2608661137 @default.
• W4293720562 hasRelatedWork W2962230309 @default.
• W4293720562 hasRelatedWork W4294990527 @default.
• W4293720562 hasRelatedWork W4318245710 @default.

• next